Introduction:
The problems of GCs administration safety in MS patients have not been solved yet because of their side effects, absence of the alternative treatment for acute relapse onset and its rapid progression.

Aim:
To analyze clinical and pharmaceutical aspects of GCs rational use in practical treatment of MS patients throughout studying of physicians’ adherence to follow the recommendation of avoiding their side effects.

Material and methods:
This is a retrospective study of 50 randomized MS case histories.

Results and discussion:
Twenty two (44 %) of MS patients had clinical and anamnestic risk factors for GCs use. However, GCs have been prescribed in 27 cases (54 %) of current hospitalization, in 26 (52 %) of patients’ anamnesis, and 38 (76 %) of patients, totally. During a hospital stage 44.44 % received pulse therapy, 59.26 % - oral GCs and 11.11 % - endolumbal administration. GCs were frequently used in MS onset during current hospitalization and in SPMS in pre-hospital period. Approximately 91 % with EDSS 5-6 were treated with GCs. We have observed possible side effects of GCs in 31.58 % among 38 MS cases treated with CGs, however, the patients have not been properly examined for their estimation. We have discovered that physicians paid more attention to prevention of gastrointestinal side effect of GCs (51.85 %), than osteoporosis. We also found 3 cases (11.11 %) of irrational combinations of GCs with NSAIDs.

Conclusions:
GCs are frequently and effectively prescribed to MS patients, their side effects are still under proper control in clinical practice.